CENTESSA PHARMACEUTICALS-ADR (CNTA)

US1523091007 - ADR

17.16  -0.39 (-2.22%)

After market: 17.16 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CNTA. CNTA was compared to 565 industry peers in the Biotechnology industry. The financial health of CNTA is average, but there are quite some concerns on its profitability. CNTA has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTA had negative earnings in the past year.
CNTA had a negative operating cash flow in the past year.
CNTA had negative earnings in each of the past 5 years.
CNTA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CNTA has a Return On Assets (-41.94%) which is comparable to the rest of the industry.
CNTA has a Return On Equity (-63.95%) which is in line with its industry peers.
Industry RankSector Rank
ROA -41.94%
ROE -63.95%
ROIC N/A
ROA(3y)-50.38%
ROA(5y)-53.58%
ROE(3y)-68.59%
ROE(5y)-117.32%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNTA has more shares outstanding
The debt/assets ratio for CNTA is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 7.39 indicates that CNTA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.39, CNTA belongs to the best of the industry, outperforming 84.52% of the companies in the same industry.
CNTA has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.32, CNTA is not doing good in the industry: 71.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 7.39
ROIC/WACCN/A
WACC9.11%

2.3 Liquidity

A Current Ratio of 8.00 indicates that CNTA has no problem at all paying its short term obligations.
CNTA's Current ratio of 8.00 is fine compared to the rest of the industry. CNTA outperforms 72.78% of its industry peers.
CNTA has a Quick Ratio of 8.00. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.00, CNTA is in the better half of the industry, outperforming 72.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8
Quick Ratio 8

More info and screens

0

3. Growth

3.1 Past

CNTA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.71%.
EPS 1Y (TTM)6.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.17%
EPS Next 2Y-0.11%
EPS Next 3Y-3.55%
EPS Next 5Y7.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CNTA's earnings are expected to decrease with -3.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.11%
EPS Next 3Y-3.55%

More info and screens

0

5. Dividend

5.1 Amount

CNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (12/20/2024, 8:03:27 PM)

After market: 17.16 0 (0%)

17.16

-0.39 (-2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners67.19%
Inst Owner Change18.94%
Ins Owners1.44%
Ins Owner Change-4.13%
Market Cap2.26B
Analysts87.14
Price Target29 (69%)
Short Float %2.93%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.28%
Min EPS beat(2)22.59%
Max EPS beat(2)23.96%
EPS beat(4)3
Avg EPS beat(4)17.22%
Min EPS beat(4)-25.91%
Max EPS beat(4)48.23%
EPS beat(8)6
Avg EPS beat(8)9.39%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.74%
PT rev (3m)96.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)5.96%
EPS NY rev (3m)6.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 330.14
P/FCF N/A
P/OCF N/A
P/B 9.58
P/tB 9.58
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0.05
BVpS1.79
TBVpS1.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.94%
ROE -63.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.38%
ROA(5y)-53.58%
ROE(3y)-68.59%
ROE(5y)-117.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.86%
Cap/Sales 2.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8
Quick Ratio 8
Altman-Z 7.39
F-Score3
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)510.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
EPS Next Y0.17%
EPS Next 2Y-0.11%
EPS Next 3Y-3.55%
EPS Next 5Y7.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.94%
EBIT Next 3Y-16.5%
EBIT Next 5YN/A
FCF growth 1Y20.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.05%
OCF growth 3YN/A
OCF growth 5YN/A